{"analyses":[{"ciLowerLimit":"57.0","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"77.3","estimateComment":"Stratified Mantel-Haenszel with stratification factors based on IRT.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Stratified by tumor location (lower limb/all other) and region (U.S./non-U.S.) based on IRT.","paramType":"Difference in ORR","paramValue":"67.2","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.3","upperLimit":"77.4","value":"67.5"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"8.8","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"TVS is a semi-quantitative magnetic resonance imaging (MRI) scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor. ORR was the percentage of participants who achieved either CR or PR as assessed by blinded IRR using TVS.\n\n* CR: Lesion completely gone\n* PR: ≥50% decrease in volume score relative to Baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 30 mg BIW vimseltinib for 24 weeks.","id":"OG000","title":"Vimseltinib"},{"description":"Participants received matching placebo BIW for 24 weeks.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The ITT Set consisted of participants who were randomized to a study treatment regimen.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 25 (Cycle 7, Day 1)","title":"ORR at Week 25 Per Tumor Volume Score (TVS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}